Table 1 Baseline demographics of study patients
Number of patients | 1317 |
Age (years, mean ± standard deviation [SD]) | 64 ± 13 |
Male/female (%) | 78/22 |
Etiology of cirrhosis (%) | |
 Hepatitis B | 721 (55) |
 Hepatitis C | 349 (27) |
 Alcoholism | 308 (23) |
Serum biochemistry (mean ± SD) | |
 Albumin (g/dL) | 3.6 ± 0.6 |
 Bilirubin (mg/dL) | 1.4 ± 2.2 |
 Creatinine (mg/dL) | 1.2 ± 1.3 |
 Estimated glomerular filtration rate (ml/min/1.73m2) | 78 ± 36 |
 International normalized ratio of prothrombin time | 1.1 ± 0.1 |
Child-Turcotte-Pugh class A/B (%) | 69/31 |
Number and size of tumor (%) | |
 Single/multiple | 59/41 |
 ≤ 5 cm/ >  5 cm | 36/64 |
Total tumor volume (cm3, mean ± SD [median]) | 566 ± 861 (193) |
Vascular invasion (%) | 591 (45) |
Metastasis/lymph node | 198 (15) |
α-fetoprotein (ng/mL, mean ± SD [median]) | 34,136 ± 177,031 (118) |
Tumor burden 0/1/2/3 (%) | 4.5/17.2/28.3/50 |
Ascites (%) | 398 (30) |
Performance status 0/1/2 (%) | 24/53/23 |
Diabetes mellitus (%) | 358 (27) |
Treatment modality (%) | |
 Resection | 282 (21) |
 Transplantation | 4 (0.3) |
 Ablation | 149 (11) |
 Transarterial chemo-embolization | 437 (33) |
 Targeted therapy | 107 (8) |
 Best supportive care | 338 (26) |